NCT02044809

Cannabidiol: a Novel Intervention for Cannabis Use Problems?

A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: 16 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use over four treatment weeks. Stage two will determine whether the MED identified in stage 1 can offer an effective treatment for cannabis dependence.

Conditions

• Cannabis Use Disorder

Interventions

Type	Name	Description
DRUG	Cannabidiol
DRUG	Placebo

Timeline

• Start date: 2014-03-01
• Primary completion: 2017-02-09
• Completion: 2017-06-05
• First posted: 2014-01-24
• Last updated: 2018-10-24

Locations

1 site across 1 country: United Kingdom